Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma

Ibrutinib (Imbruvica®), a small-drug inhibitor of Bruton tyrosine kinase (BTK), is currently undergoing clinical testing in patients with multiple myeloma (MM), yet important questions on the role of BTK in myeloma biology and treatment are outstanding. Using flow-sorted side population (SP) cells f...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Res
Autors principals: Yang, Ye, Shi, Jumei, Gu, Zhimin, Salama, Mohamed E, Das, Satyabrata, Wendlandt, Erik, Xu, Hongwei, Huang, Junwei, Tao, Yi, Hao, Mu, Franqui, Reinaldo, Levasseur, Dana, Janz, Siegfried, Tricot, Guido, Zhan, Fenghuang
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4384656/
https://ncbi.nlm.nih.gov/pubmed/25589346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-2362
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars